Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma (Q37310407)

19 August 2017

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma (English)

1 reference

19 August 2017

1 reference

8

Paul Richardson

1 reference

19 August 2017

4

Ruben Niesvizky

1 reference

19 August 2017

Robert Douglas Knight

16

object named as

Robert D Knight

1 reference

19 August 2017

6

Edward A Stadtmauer

1 reference

19 August 2017

10

Shaji Kumar

1 reference

19 August 2017

Christine Chen

1

1 reference

19 August 2017

Donna E Reece

2

1 reference

19 August 2017

David Siegel

3

1 reference

19 August 2017

Ralph V Boccia

5

1 reference

19 August 2017

Rafat Abonour

7

1 reference

19 August 2017

Jeffrey Matous

9

1 reference

19 August 2017

Nizar J Bahlis

11

1 reference

19 August 2017

Melissa Alsina

12

1 reference

19 August 2017

Robert Vescio

13

1 reference

19 August 2017

Steven E Coutre

14

1 reference

19 August 2017

Dennis Pietronigro

15

1 reference

19 August 2017

Jerome B Zeldis

17

1 reference

19 August 2017

Vincent Rajkumar

18

1 reference

19 August 2017

language of work or name

English

0 references

publication date

26 May 2009

1 reference

British Journal of Haematology

19 August 2017

1 reference

19 August 2017

146

1 reference

19 August 2017

2

1 reference

19 August 2017

164-170

1 reference

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

A phase 2 study of bortezomib in relapsed, refractory myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

Antitumor activity of thalidomide in refractory multiple myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2728892

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel

2 September 2018

1 reference

12 December 2020

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha

1 reference

12 December 2020

Lenalidomide and venous thrombosis in multiple myeloma

1 reference

12 December 2020

Multiple myeloma. Clinical practice guidelines in oncology

1 reference

12 December 2020

Thalidomide in the treatment of relapsed multiple myeloma

1 reference

12 December 2020

10.1111/J.1365-2141.2009.07728.X

Identifiers

DOI

1 reference

19 August 2017

1 reference

19 August 2017

1 reference